Overview
AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor
Status:
Completed
Completed
Trial end date:
2013-02-01
2013-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to determine the recommended dose of the combination of AVE8062 with platinum salts (cisplatin or carboplatin) and taxanes (docetaxel or paclitaxel) in patients with advanced solid tumors for which platinum-taxane doublet constitutes mainstay of care.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
SanofiTreatments:
Taxane
Criteria
Inclusion Criteria:- Advanced neoplastic disease (i.e. metastatic or locally advanced disease) for which
platinum-taxane doublet regimens are approved or constitutes the mainstay of care such
as non small cell lung cancer, epithelial ovary cancer, gastric cancer, transitional
cell and bladder cancer and head and neck cancer.
- Eastern cooperative oncology group (ECOG) performance status of 0 to 1.
Exclusion Criteria:
- Concurrent treatment with any other anticancer therapy, including chemotherapy,
immunotherapy, radiotherapy (excluding radiotherapy with palliative intent on
non-target lesions), targeted therapy, gene therapy, or patients planning to receive
these treatments during the study.
- Absence of histologically or cytologically proven cancer at the first diagnosis.
- Negative serum/urinary pregnancy test
- Washout period of 3 weeks for prior anti-tumor therapy or any investigational
treatment
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.